{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T23:03:32Z","timestamp":1792710212470,"version":"4.5.0"},"reference-count":21,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2007,7,1]],"date-time":"2007-07-01T00:00:00Z","timestamp":1183248000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2007,7,1]],"date-time":"2007-07-01T00:00:00Z","timestamp":1183248000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015362","name":"Amicus Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015362","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2007,7]]},"DOI":"10.1016\/j.bbrc.2007.05.082","type":"journal-article","created":{"date-parts":[[2007,5,24]],"date-time":"2007-05-24T03:39:32Z","timestamp":1179977972000},"page":"168-173","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"title":["Screening for pharmacological chaperones in Fabry disease"],"prefix":"10.1016","volume":"359","author":[{"given":"Sang-Hoon","family":"Shin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary J.","family":"Murray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Kluepfel-Stahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adele M.","family":"Cooney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane M.","family":"Quirk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael","family":"Schiffmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roscoe O.","family":"Brady","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine R.","family":"Kaneski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbrc.2007.05.082_bib1","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1056\/NEJM196705252762101","article-title":"Enzymatic defect in Fabry\u2019s disease. Ceramidetrihexosidase deficiency","volume":"276","author":"Brady","year":"1967","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbrc.2007.05.082_bib2","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/BF00697017","article-title":"Neuropathological and biochemical studies in Fabry\u2019s disease","volume":"30","author":"Tabira","year":"1974","journal-title":"Acta Neuropathol. (Berl.)"},{"key":"10.1016\/j.bbrc.2007.05.082_bib","series-title":"The Metabolic and Molecular Bases of Inherited Disease","first-page":"3733","article-title":"\u03b1-Galactosidase A deficiency: Fabry disease","author":"Desnick","year":"2001"},{"key":"10.1016\/j.bbrc.2007.05.082_bib4","series-title":"Mendelian Inheritance in Man","author":"McKusick","year":"1998"},{"key":"10.1016\/j.bbrc.2007.05.082_bib5","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1146\/annurev.med.57.110104.115650","article-title":"Enzyme replacement for lysosomal diseases","volume":"57","author":"Brady","year":"2006","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.bbrc.2007.05.082_bib6","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s00428-005-0089-x","article-title":"Pathological findings in a patient with Fabry disease who died after 2.5years of enzyme replacement","volume":"448","author":"Schiffmann","year":"2006","journal-title":"Virchows Arch."},{"key":"10.1016\/j.bbrc.2007.05.082_bib7","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/S0140-6736(00)02161-9","article-title":"Novel oral treatment of Gaucher\u2019s disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis","volume":"355","author":"Cox","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.bbrc.2007.05.082_bib8","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1038\/nrn1725","article-title":"Storage solutions: treating lysosomal disorders of the brain","volume":"6","author":"Jeyakumar","year":"2005","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.bbrc.2007.05.082_bib9","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0165-6147(03)00158-5","article-title":"A contradictory treatment for lysosomal storage disorders: inhibitors enhance mutant enzyme activity","volume":"24","author":"Fan","year":"2003","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.bbrc.2007.05.082_bib10","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/4801","article-title":"Accelerated transport and maturation of lysosomal alpha-galactosidase A in Fabry lymphoblasts by an enzyme inhibitor","volume":"5","author":"Fan","year":"1999","journal-title":"Nat. Med."},{"key":"10.1016\/j.bbrc.2007.05.082_bib11","doi-asserted-by":"crossref","first-page":"15912","DOI":"10.1073\/pnas.2536657100","article-title":"Chemical chaperone therapy for brain pathology in G(M1)-gangliosidosis","volume":"100","author":"Matsuda","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bbrc.2007.05.082_bib12","doi-asserted-by":"crossref","first-page":"15428","DOI":"10.1073\/pnas.192582899","article-title":"Chemical chaperones increase the cellular activity of N370S beta-glucosidase: a therapeutic strategy for Gaucher disease","volume":"99","author":"Sawkar","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bbrc.2007.05.082_bib13","doi-asserted-by":"crossref","first-page":"13478","DOI":"10.1074\/jbc.M308523200","article-title":"Pharmacological enhancement of beta-hexosaminidase activity in fibroblasts from adult Tay-Sachs and Sandhoff patients","volume":"279","author":"Tropak","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbrc.2007.05.082_bib14","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1056\/NEJM200107053450104","article-title":"Improvement in cardiac function in the cardiac variant of Fabry\u2019s disease with galactose-infusion therapy","volume":"345","author":"Frustaci","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbrc.2007.05.082_bib15","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.bbadis.2004.07.001","article-title":"Transgenic mouse expressing human mutant alpha-galactosidase A in an endogenous enzyme deficient background: a biochemical animal model for studying active-site specific chaperone therapy for Fabry disease","volume":"1690","author":"Ishii","year":"2004","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.bbrc.2007.05.082_bib16","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1096\/fj.04-2375com","article-title":"A synthetic chaperone corrects the trafficking defect and disease phenotype in a protein misfolding disorder","volume":"19","author":"Yam","year":"2005","journal-title":"FASEB J."},{"key":"10.1016\/j.bbrc.2007.05.082_bib17","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/S0021-9258(17)38286-8","article-title":"Purification and properties of the two major isozymes of alpha-galactosidase from human placenta","volume":"253","author":"Kusiak","year":"1978","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbrc.2007.05.082_bib18","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/0009-8981(81)90384-3","article-title":"Differential assay for lysosomal alpha-galactosidases in human tissues and its application to Fabry\u2019s disease","volume":"112","author":"Mayes","year":"1981","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.bbrc.2007.05.082_bib19","doi-asserted-by":"crossref","first-page":"3450","DOI":"10.1073\/pnas.0537900100","article-title":"Long-term correction of globotriaosylceramide storage in Fabry mice by recombinant adeno-associated virus-mediated gene transfer","volume":"100","author":"Park","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bbrc.2007.05.082_bib20","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1182\/blood.V57.3.379.379","article-title":"Human T-lymphocyte growth factor: regulation of growth and function of T lymphocytes","volume":"57","author":"Ruscetti","year":"1981","journal-title":"Blood"},{"key":"10.1016\/j.bbrc.2007.05.082_bib21","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1002\/humu.20144","article-title":"Detection of alpha-galactosidase a mutations causing Fabry disease by denaturing high performance liquid chromatography","volume":"25","author":"Shabbeer","year":"2005","journal-title":"Hum. Mutat."}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X07010558?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X07010558?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T10:34:07Z","timestamp":1757759647000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X07010558"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,7]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,7]]}},"alternative-id":["S0006291X07010558"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2007.05.082","relation":{},"ISSN":["0006-291X"],"issn-type":[{"value":"0006-291X","type":"print"}],"subject":[],"published":{"date-parts":[[2007,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Screening for pharmacological chaperones in Fabry disease","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2007.05.082","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}